[go: up one dir, main page]

WO1998009992A3 - Htm4, methods of treatment and assays, agonists and antagonists - Google Patents

Htm4, methods of treatment and assays, agonists and antagonists Download PDF

Info

Publication number
WO1998009992A3
WO1998009992A3 PCT/US1997/015510 US9715510W WO9809992A3 WO 1998009992 A3 WO1998009992 A3 WO 1998009992A3 US 9715510 W US9715510 W US 9715510W WO 9809992 A3 WO9809992 A3 WO 9809992A3
Authority
WO
WIPO (PCT)
Prior art keywords
htm4
agonists
antagonists
protein
assays
Prior art date
Application number
PCT/US1997/015510
Other languages
French (fr)
Other versions
WO1998009992A2 (en
Inventor
Bing Lim
Chaker N Adra
Jean-Michel Lelias
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Priority to AU41784/97A priority Critical patent/AU4178497A/en
Priority to JP10512862A priority patent/JP2001500013A/en
Priority to CA002264490A priority patent/CA2264490A1/en
Priority to EP97939769A priority patent/EP0931096A2/en
Publication of WO1998009992A2 publication Critical patent/WO1998009992A2/en
Publication of WO1998009992A3 publication Critical patent/WO1998009992A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a recombinant DNA molecule which encodes a HTm4 protein, a transformed host cell which has been stably transfected with a DNA molecule which encodes a HTm4 protein and a recombinant HTm4 protein. The invention also relates to a method for detecting the presence of a hereditary atopy, to agonists and antagonists of a HTm4 protein, and to their diagnostic and therapeutic use.
PCT/US1997/015510 1996-09-03 1997-09-02 HTm4, METHODS OF TREATMENT AND ASSAYS, AGONISTS AND ANTAGONISTS WO1998009992A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU41784/97A AU4178497A (en) 1996-09-03 1997-09-02 HTm4, methods of treatment and assays, agonists and antagonists
JP10512862A JP2001500013A (en) 1996-09-03 1997-09-02 HT (m4), treatment and assay methods, agonists and antagonists
CA002264490A CA2264490A1 (en) 1996-09-03 1997-09-02 Htm4, methods of treatment and assays, agonists and antagonists
EP97939769A EP0931096A2 (en) 1996-09-03 1997-09-02 HT m4?, METHODS OF TREATMENT AND ASSAYS, AGONISTS AND ANTAGONISTS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/707,340 US5705615A (en) 1994-10-06 1996-09-03 Antibodies specific for HTm4
US08/707,340 1996-09-03

Publications (2)

Publication Number Publication Date
WO1998009992A2 WO1998009992A2 (en) 1998-03-12
WO1998009992A3 true WO1998009992A3 (en) 1998-04-23

Family

ID=24841303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015510 WO1998009992A2 (en) 1996-09-03 1997-09-02 HTm4, METHODS OF TREATMENT AND ASSAYS, AGONISTS AND ANTAGONISTS

Country Status (6)

Country Link
US (2) US5705615A (en)
EP (1) EP0931096A2 (en)
JP (1) JP2001500013A (en)
AU (1) AU4178497A (en)
CA (1) CA2264490A1 (en)
WO (1) WO1998009992A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
WO2000006170A1 (en) * 1998-07-31 2000-02-10 The Trustees Of The University Of Pennsylvania Inhibitors of herpesvirus gene expression, replication and pathogenesis
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US20040137566A1 (en) * 2001-12-10 2004-07-15 Tedder Thomas F. Identification of novel ms4a gene family members expressed by hematopoietic cells
CN1980696B (en) * 2004-04-30 2012-09-26 血液分离生物技术有限公司 Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
WO2006078783A2 (en) * 2005-01-18 2006-07-27 Chaker, Adra N. Htm4 used for cell-cycle regulation through its interaction with kap
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033051A1 (en) * 1994-05-27 1995-12-07 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5552312A (en) * 1994-10-06 1996-09-03 Beth Israel Hospital Boston Recombinant HTm4 gene, protein and assays

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005481A1 (en) * 1993-08-18 1995-02-23 Isis Innovation Limited Diagnostic method and therapy
IL114417A0 (en) * 1994-07-07 1995-10-31 Res Dev Foundation Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
ZA955430B (en) * 1994-07-07 1997-02-13 Res Dev Foundation Tumor necrosis factor receptor-ii associated protein kinase and method for their use
FI955073A7 (en) * 1995-10-25 1997-04-26 Oy Kansio Aitta Ab Storage case and method for manufacturing a storage case

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033051A1 (en) * 1994-05-27 1995-12-07 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5552312A (en) * 1994-10-06 1996-09-03 Beth Israel Hospital Boston Recombinant HTm4 gene, protein and assays

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. ADRA ET AL.: "Cloning of the cDNA for a hematopoietic cell-specific protein related to CD20 and the beta subunit of the high-affinity IgE receptor: Evidence for a family of proteins with four membrane-spanning regions.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 91, no. 21, 11 October 1994 (1994-10-11), WASHINGTON, DC, USA, pages 10178 - 10182, XP002055015 *
C. ADRA ET AL.: "HTM4, a four-transmembrane hematopoietic specific protein, interacts with tumor necrosis factor receptor associated factor 2.", BLOOD, vol. 88, no. 10 suppl. 1 part 1-2, 15 November 1996 (1996-11-15), NEW YORK, NY, USA, pages 340A, XP002055016 *

Also Published As

Publication number Publication date
CA2264490A1 (en) 1998-03-12
JP2001500013A (en) 2001-01-09
AU4178497A (en) 1998-03-26
EP0931096A2 (en) 1999-07-28
WO1998009992A2 (en) 1998-03-12
US5972688A (en) 1999-10-26
US5705615A (en) 1998-01-06

Similar Documents

Publication Publication Date Title
WO1999000410A3 (en) Human extracellular matrix proteins
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
WO1999061471A3 (en) Human transmembrane proteins
WO2001012662A3 (en) Membrane associated proteins
WO1999036550A3 (en) Human protease molecules
WO1999024463A3 (en) Signal peptide-containing proteins
EP0825260A3 (en) Arginase II
WO2000018922A8 (en) Human carbohydrate-associated proteins
WO2000012711A8 (en) Human membrane channel proteins
WO2000009709A3 (en) Proteases and associated proteins
WO1998009992A3 (en) Htm4, methods of treatment and assays, agonists and antagonists
WO2000012703A3 (en) Protein transport-associated molecules
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO2001005970A3 (en) Gtp-binding protein associated factors
WO1999033870A3 (en) Human regulatory proteins
WO2000052151A3 (en) Human secretory proteins
WO1999058558A3 (en) Cell signaling proteins
WO2000056891A3 (en) Human transmembrane proteins
WO1998055509A3 (en) Two human dnaj-like proteins
WO2001044448A3 (en) Human oxidoreductase proteins
WO1999061614A3 (en) Human socs proteins
WO1999041373A3 (en) Human transport-associated molecules
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
WO2000065054A3 (en) Human membrane-associated proteins
WO1999049037A3 (en) Protein phosphatase-related molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264490

Country of ref document: CA

Ref country code: CA

Ref document number: 2264490

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 512862

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997939769

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997939769

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997939769

Country of ref document: EP